Physician profile
Andrew D Schmidt
NPI 1598740037
$6,841.46
in general payments reported to CMS, 2019-2025
25 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $868 · 2021: $1,159 · 2022: $2,410 · 2023: $834 · 2024: $125 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,513.45 | 2019-2024 | Linzess, Rinvoq, Skyrizi |
| Pfizer INC. | $707.59 | 2019-2025 | |
| Janssen Biotech, INC. | $664.91 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.76 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $358.25 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $348.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $312.20 | 2021-2022 | |
| Celgene Corporation | $224.44 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $161.31 | 2022 | |
| Janssen Scientific Affairs, LLC | $120.83 | 2022 | |
| Vivus LLC | $119.18 | 2020-2022 | |
| Madrigal Pharmaceuticals | $114.80 | 2025 | Rezdiffra |
| Genzyme Corporation | $111.65 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $99.11 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $67.27 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $65.36 | 2020 | |
| Intercept Pharmaceuticals, INC. | $55.78 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $53.97 | 2021-2023 | |
| Amgen INC. | $42.43 | 2021 | |
| Daiichi Sankyo INC. | $38.24 | 2019-2022 | |
| Ethicon US, LLC | $37.43 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.95 | 2022 | |
| Endo Pharmaceuticals INC. | $19.19 | 2019 | |
| Braintree Laboratories, INC. | $18.68 | 2021 | |
| Sanofi Pasteur INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.